LONDON — Real-world evidence for patients with rheumatic and musculoskeletal diseases was presented at the 2026 European Alliance of Associations for Rheumatology annual Congress in London. The congress served as a venue for the presentation of this evidence. The event took place in London in 2026.
Results from the ANCHOR-RA study presented at the 2026 European Alliance of Associations for Rheumatology Congress showed that 9.1 percent of enrolled participants had undiagnosed interstitial lung disease. The study presented these specific results at the congress. The percentage applied to the enrolled participants in the study.
The ANCHOR-RA study is an international cross-sectional prospective study. It was designed to develop a multivariable model to detect interstitial lung disease in rheumatoid arthritis patients. The design focused on the development of the detection model.
Researchers enrolled 1,169 participants with rheumatoid arthritis for the study. The participants had at least two interstitial lung disease risk factors. They had no known interstitial lung disease at the time of enrollment. The enrollment criteria specified these risk factor thresholds.
Preliminary analyses associated older age with rheumatoid arthritis-associated interstitial lung disease. Male sex was associated with the condition, and greater tobacco exposure was associated. Higher rheumatoid arthritis disease activity was associated as well. These factors were linked to the condition in the analyses.
Lung-based factors associated with rheumatoid arthritis-associated interstitial lung disease included lower oxygen saturation. Reduced lung diffusion results were included in the factors. Crackles on auscultation were included, and the MUC5B promoter variant was included. The list comprised multiple lung-based indicators.
Separately, researchers concluded that population-level primary prevention efforts in Switzerland have been less effective in men. These men subsequently develop rheumatoid arthritis. The conclusion addressed prevention efforts and their effectiveness. The findings focused on the demographic of men.
Weight loss for glucagon-like peptide-1 receptor agonist users plateaued after 12 months. The finding concerned glucagon-like peptide-1 receptor agonist users. The plateau occurred after 12 months of use. This data described the timeline for the weight loss plateau.
No independent assessment was available for this report.